Idorsia Pharmaceuticals Ltd
Idorsia to debut at the 39th J.P. Morgan Healthcare Conference – Major catalysts expected in the near-term – Daridorexant NDA submitted to the US FDA
Idorsia to debut at the 39th J.P. Morgan Healthcare Conference – Major catalysts expected in the near-term – Daridorexant NDA submitted to the US FDA
• Daridorexant new drug application (NDA) submitted to the US Food & Drug Administration (FDA) on January 8, 2021
Allschwil, Switzerland – January 11, 2021
Idorsia Ltd (SIX: IDIA) today announced that Jean-Paul Clozel, Chief Executive Officer of Idorsia, will present at the 39
th J. P. Morgan Healthcare Conference on January 12, 2021 at 09:10 Eastern Time / 15:10 Central European Time. The conference will take place fully virtual.